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Early onset epileptic encephalopathies that
occur in very early childhood are rare but
particularly catastrophic forms of epilepsy
that are invariably associated with sig-
nificant neurological morbidity (Nordli,
2012). Mutations in the Syntaxin Binding
Protein 1 (STXBP1) gene have been linked
with two distinct but related forms of
the disorder including early onset epileptic
encephalopathy with suppression-bursts
(EESB) associated with Ohtahara syn-
drome, and more recently with infantile
spasms (IS) associated with West syn-
drome (Barcia et al., 2013). Mutations
in patients are not inherited but rather
found to occur de novo in a single copy of
the STXBP1 gene. Ohtahara syndrome is
the earliest appearing age-related epileptic
encephalopathy with seizures first present-
ing as early as the neonatal period and
is diagnosed with a characteristic burst-
suppression pattern on EEG (Yamatogi
and Ohtahara, 2002). It is an extremely
debilitating neurological disorder, involv-
ing intractable frequent daily seizures and
severe intellectual disability. Patients often
do not survive beyond early childhood.
West syndrome can present with frequent
daily IS-type seizures within the first few
weeks but more typically within the first
few months of life and is diagnosed by a
characteristic hypsarrhythmia pattern on
EEG (Wong and Trevethan, 2001). The
majority of patients have some degree
of developmental delay and go on to
have mild to severe intellectual disability.
Later in life, symptoms of Ohtahara syn-
drome patients can sometimes evolve into
those usually associated with West syn-
drome, where the seizure-types become
more reminiscent of IS and the burst-
suppression pattern on EEG evolves into
hypsarrhythmia.
There is currently no cure for Ohtahara
syndrome or West syndrome and current
therapy, which consists of generic anti-
convulsant medication, is largely unsat-
isfactory due to the refractory nature
of the seizures. To date, STXBP1 muta-
tions have been reported in 27 cases of
EESB and 7 cases of IS not preceded by
EESB/Ohtahara syndrome (Barcia et al.,
2013). Whereas most genes associated
with epileptic disorders encode ion chan-
nels or neurotransmitter receptor subunits,
STXBP1 is thefirst epilepsy-associatedgene
with a direct role in the neurotransmitter
release process (Poduri and Lowenstein,
2011). The presence of STXBP1 protein
is necessary for neurotransmitter release
in probably all neuron types in the brain
(Verhage et al., 2000). However, it may
be likely that impaired neurotransmitter
release in inhibitory GABAergic interneu-
rons throughout thebrain results inuncon-
trolled synchronous firing of excitatory
neurons in regions, resulting in epilep-
tic foci. Indeed, a patient with an STXBP1
mutation was recently reported to have
responded well to Vigabatrin (Romaniello
et al., 2013), a drugwhichworks specifically
by inhibiting the gamma-aminobutyric
acid transaminase enzyme responsible for
the breakdown of GABA. In this article
a potential route toward the development
of a targeted anticonvulsant medication
for STXBP1-associated epilepsy will be
presented. The proposal is based on the
refined model of neurotransmitter release
suggested by recent findings in the Josep
Rizo laboratory (Ma et al., 2013) and also
the huge potential held in the field of




In neurons, the central molecular machin-
ery involved in mediating rapid exocytosis
of neurotransmitter-containing synaptic
vesicles are the soluble N-ethylmaleimide-
sensitive factor attachment protein recep-
tors (SNAREs) (Rizo and Südhof, 2012).
Two of these SNAREs, syntaxin1a and
SNAP25 are located within the presynap-
tic plasma membrane whereas the third,
synaptobrevin2 is located within themem-
brane of the synaptic vesicle. All three
proteins contain SNARE domain(s) which
can assume alpha-helical conformations
when interacting with other SNAREmotifs
(Fasshauer et al., 1997). The assembly
of SNARE motifs from the three pro-
teins into very stable hetero-oligomeric
four-helix bundles, known as the SNARE
fusion complex, induces fusion of the
synaptic vesicle membrane to the presy-
naptic plasma membrane resulting in
neurotransmitter release into the synap-
tic cleft. However, the detailed molecular
mechanisms by which the SNARE fusion
complex is assembled and regulated have
not been fully elucidated. It is known
that syntaxin1a and SNAP25 can form
stable SNARE complexes which do not
include Synaptobrevin 2, but also consist
of four-helix bundles that are constitu-
tively present in the presynaptic plasma
membrane; however, these are incapable of
participating directly in membrane fusion.
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These non-productive complexes which
result largely from the promiscuity of the
syntaxin1a SNARE domain to form stable
complexes with other SNARE motifs most
likely constitute kinetic traps that hinder
SNARE fusion complex assembly (Rizo
and Südhof, 2012), and their disassem-
bly is likely important for the liberation
of individual monomers that can partic-
ipate in proper SNARE fusion complex
assembly.
The formation of the SNARE fusion
complex in vivo is also known to require
additional factors including STXBP1 (also
known as Munc18) and Munc13, and
indeed neurotransmitter release is com-
pletely abolished in STXBP1-deficient cells
(Verhage et al., 2000). However, the role
of STXBP1 in neurotransmitter release
had been paradoxical since STXBP1 is
known to bind tightly to a “closed” con-
formation of syntaxin1a locking it in this
mode inhibitory to SNARE fusion com-
plex assembly (Burkhardt et al., 2008). A
recent elegant study more clearly defined
the roles of STXBP1 and Munc13 in
SNARE fusion complex assembly and has
helped refine our model of neurotrans-
mitter release (Ma et al., 2013). The results
of Ma et al. showed that STXBP1 is also
important for the displacement of SNAP25
from syntaxin1a and the disassembly of
the non-productive SNARE complexes.
They propose that the resulting binding
of STXBP1 to a disassembled syntaxin1a
monomer in its closed conformation in
fact represents the first active step of fusion
complex assembly. Their results also show
that Munc13 appears to be critical for
transforming syntaxin1a from the “closed”
to the “open” confirmation during the
actual fusion complex assembly process.
Therefore whereas STXBP1 plays a role
in disassembling non-productive SNARE
complexes and thus capturing individ-
ual syntaxin1a monomers in their closed
conformation, Munc13 then acts to open
syntaxin1a at the right moment so that the
correct configuration of SNARE complex,
including synaptobrevin2 SNARE motifs,
can be formed during the membrane
fusion process.
THE POTENTIAL OF DRUG DESIGN
TARGETED FOR STXBP1
HAPLOINSUFFICIENCY
The findings of Ma et al. were most
intriguing as it suggested a novel role
for STXBP1 in the disassembly of
non-productive SNARE complexes and
the resulting generation of a productive
STXBP1-syntaxin1a sub-complex start-
ing point of SNARE fusion complex
assembly. Indeed, due to their stability,
the disassembly of the non-productive
SNARE complexes may represent a slow
rate-limiting step in the pathway toward
productive fusion complex assembly.
Thus in situations where the num-
ber of functional STXBP1 molecules
is reduced, such as occurs in STXBP1
haploinsufficieny, progress through the
neurotransmitter release pathway is likely
to be severely compromised. It may be
possible however that increasing the
incidence of disassembled syntaxin1a
monomers in the presynaptic plasma
membrane would counterbalance situa-
tions where there is a reduced amount
of STXBP1 molecules so that the balance
of syntaxin1a-STXBP1 complex forma-
tion is restored (Figure 1). One potential
mechanism of increasing the number of
free syntaxin1a monomers in the presy-
naptic membrane is to introduce small
molecules which can disassemble/inhibit
the non-productive SNARE complexes.
Such an approach may be especially
appealing since if these complexes really
are non-functional, then it would follow
that the inhibition of these complexes
in vivo would cause very little side-effects.
Another key consideration is the fact
that the syntaxin1a-SNAP25 interaction
also occurs in the functional SNARE
fusion core complex and its structural
elements appear largely indistinguish-
able in nature form its non-productive
counterpart (Margittai et al., 2001; Xiao
et al., 2001); thus this particular inter-
action should not be targeted. Instead,
the syntaxin1a:syntaxin1a SNARE inter-
action is unique to the non-productive
SNARE complexes and since these com-
plexes are most stable as four-helix
bundles, successful disruption of this
interaction would most likely lead to
destabilization and disassembly of the
whole complex. Thus the drug design
of a PPI inhibitor which targets the
alpha-helical syntaxin1a:syntaxin1a inter-
action, which occurs specifically within
non-productive SNARE complexes, is sug-
gested for the potential use in STXBP1
haploinsufficiency-associated epileptic
disorders.
PPI INHIBITORS AND THEIR ABILITY
IN TARGETING ALPHA HELICAL
INTERACTIONS
Targeting protein-protein interfaces of
multiprotein complexes has become
a significant focus in drug discovery
(Higueruelo et al., 2013). Alpha-helices
comprise approximately 40% of all protein
secondary structures and they repre-
sent fundamental recognition elements
in many PPIs. In recent years, significant
effort has been directed to develop pep-
tidic and non-peptidic small molecules
that are structural or functional mimics
of alpha-helices and can be classed into
three major categories (Cummings and
Hamilton, 2010; Edwards and Wilson,
2011; Azzarito et al., 2013). Type I mimet-
ics are short peptidic oligomers that
recapitulate the helical conformation of
an interaction interface. Such oligomers
can be compared to miniature proteins
that occur in nature which are capa-
ble of crossing the blood-brain-barrier
such as the neurotoxic bee venom pep-
tide apamin (Nicoll et al., 2005). Type II
mimetics on the other hand are small non-
peptide chemical compounds that bind to
a peptide receptor but do not necessarily
mimic the original heilx structure and thus
serve as functional mimetics. Examples
include a family of tetra-substituted imi-
dazoles found to be capable of inhibiting
the p53/mDM2 interaction in cancer-
associated pathways (Vassilev et al., 2004).
Type III mimetics are a class of pro-
teomimetics which match the topography
of the original helix by mimicking the
spatial orientation of its key recognition
residues, rather than recapitulating the
helical conformation as observed in type
I mimetics. Such an approach has previ-
ously been used to inhibit Bcl-2 family
interactions (Yin et al., 2005).
THE PATH AHEAD
Thus several examples of the success-
ful development of alpha-helical PPI
inhibitors have been previously described
and the interested reader is referred to
previous excellent reviews (Cummings
and Hamilton, 2010; Edwards and
Wilson, 2011; Azzarito et al., 2013). The
molecular structure of the alpha-helical
syntaxin1a:syntaxin1a SNARE interface
has been characterized using site-directed
spin labeling and Electron Paramagnetic
Resonance by independent laboratories
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FIGURE 1 | Theoretical model of the early steps of the neurotransmitter
release pathway is depicted in three scenarios. Under normal conditions,
the presynaptic membrane, represented by the thin red line, contains
non-productive SNARE complexes which are incapable of directly
participating in membrane fusion and include syntaxin1a tetramers (Misura
et al., 2001b), and syntaxin1a:SNAP25 heterodimers (Xiao et al., 2001; Misura
et al., 2001a). Along with the N-ethylmaleimide-sensitive factor (NSF) and
NSF adaptor proteins (Weber et al., 2000), not shown here for the sake of
simplicity, STXBP1 is required for the disassembly of the non-productive
complexes and the capturing of syntaxin1a monomers in their closed
conformation. According to the findings of (Ma et al., 2013), these
STXBP1:syntaxin1a heterodimers represent the true starting point of
functional SNARE fusion complex assembly, and SNAP25 only becomes
re-involved in a later step of the pathway which is not shown here. In STXBP1
haploinsufficiency, the number of functional STXBP1 molecules is reduced,
resulting in less efficient disassembly of non-productive SNARE complexes
and thus reducing the number of STXBP1:syntaxin1a heterodimers present.
The less efficient production of this starting point, which may represent a
rate-limiting step of the pathway due to the general stability of SNARE
complexes, results in an impairment of eventual neurotransmitter release
(not shown here). However, increasing the number of readily-available
syntaxin1a monomers, with the use of a syntaxin1a:syntaxin1a PPI inhibitor,
may restore the balance of the STXBP1:syntaxin1a starting point formation of
fusion complex assembly in STXBP1 haploinsufficiency.
(Margittai et al., 2001; Xiao et al., 2001;
Zhang et al., 2002), and in addition the
crystal structure of the syntaxin1a SNARE
motif within SNARE complexes has been
solved (Sutton et al., 1998). Thus efforts
to design a PPI inhibitor for this interac-
tion interface should be possible and may
be warranted for potential use in STXBP1
haploinsufficiency-associated disorders. In
addition, since transgenic mouse models
harboring stxbp1 mutations are also avail-
able (Verhage et al., 2000), such a potential
PPI inhibitor could readily be tested for
its ability to alleviate neurological symp-
toms in vivo. Thus with the combination
of clinical genetics, cell biology, and struc-
tural biology knowledge at hand, and the
potential offered by PPI inhibitors in tar-
geted drug design, we could be on the way
to developing a targeted anticonvulsant
therapy for the treatment of a particularly
devastating class of epileptic disorder.
It is perhaps also noteworthy that in
stxbp1-null mice, although neurotrans-
mitter release was completely abolished,
neural differentiation and brain assem-
bly occurred normally. But apoptosis in
mature neural cells then caused neurode-
generation throughout the brain resulting
in death of the null-mice. This may be con-
sistent with the observation that anatomi-
cal brain abnormalities can be observed in
Ohtahara syndrome patients and less fre-
quently in West syndrome patients (Barcia
et al., 2013), and may suggest that apop-
tosis of mature neural cells also occurs in
these patients. However, it is likely that
the impeded neurotransmitter release in
the developed brain of STXBP1-patients
also contributes to their developmental
delay and intellectual disability, and this
raises the compelling prospect that devel-
opment of such a syntaxin1a:syntaxin1a
PPI inhibitor may have potential use in
also limiting these particular phenotypes.
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